Clinical TrialsThe initiation of dosing for SEP-631 is considered a meaningful value inflection point for Septerna.
Potential Market ImpactSEP-631 could achieve blockbuster status if it matches the efficacy of Xolair, which had significant sales in 2023.
Strategic CollaborationsThe global collaboration and license agreement between Septerna and Novo Nordisk A/S became effective, initiating joint research and development efforts to discover, develop, and commercialize multiple potential oral small molecule therapies for obesity, type 2 diabetes, and other cardiometabolic diseases.